ClinicalTrials.gg
RecruitingNCT06430372Updated May 13, 2025

Study of VEGF-A Targeting NIR-II Fluorescence Endoscopy in the Gastrointestinal Tract

A Phase 1 interventional study of Bev-ICG and NIR-II fluorescence endoscopy platform in Gastrointestinal Carcinoma, Dysplasia and Gastrointestinal Polyp, sponsored by Institute of Automation, Chinese Academy of Sciences. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-13.

Sponsored by Institute of Automation, Chinese Academy of Sciences · Phase 1, Interventional, and Screening

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Registered 10 months after the study started (first participant enrolled Jul 2023, registered May 2024).
  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Polyps with a site in China — 13 open to participants now, 15 under way, none of them phase 3. Polyps · China.

Planned enrollment
32nd of 32
30 · median 351
Started
2023
with 3 others
Phase 1
Only one
of the 51
Primary completion
2025-05
later than 3 of 14 live
Registered
36th of 51
by date

Among the 51 studies in Polyps with a site in China, this one is the 32nd largest by planned enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2023, is the only one in phase 1, reaches primary completion later than 3 of the 14 other live ones, and was the 36th registered.

Polyps

312 studies on the registry are indexed under Polyps; 59 are open to participants now.

Browse Polyps studies →

Open to participants now

13 of the 51 studies in Polyps with a site in China are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 34 Polyps studies recruiting now, 25 (74%) set no upper age limit and 6 (18%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Polyps with a site in China, or all of them as a file.
02

Study summary

In this study, the investigators are studying new ways to look for abnormal tissues of the gastrointestinal tract during an endoscopy. We are using a VEGF-A targeting fluorescent probe and a NIR-II fluorescent endoscope to help detect abnormal tissues that are hard to see by the naked eye.

The main purposes of this study include:

  1. To translate the NIR-II approach into the endoscopy, and understand its advantages and limitations on detecting abnormal tissues in gastrointestinal.
  2. To validate whether topical administration of a targeting probe can stick to abnormal tissues and be detected by the NIR-II endoscope.
  3. To validate the safety and effectiveness of the topical administration of VEGF-A targeting probes for clinical application.
03

Conditions studied

  • Gastrointestinal Carcinoma
  • Dysplasia
  • Gastrointestinal Polyp

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Known or suspected gastrointestinal lesions.
  • Scheduled for a clinically-indicated endoscopy.
  • Mentally competent person, 18 years or older.
  • Approved to sign the .
  • Adequate potential for follow-up.

Exclusion criteria

Exclusion Criteria:

  • Subjects with known allergy or negative reaction to ICG or derivatives.
  • Undesirable function of heart, lung, kidney, or any other organs.
  • Enrolled in other trials in the past 3 months.
  • Pregnant or trying to conceive.
  • Unable to tolerate an endoscopy.
  • Medical or psychiatric conditions that compromise the patient's ability to give .
  • The researchers considered inappropriate to be included.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Bev-ICG NIR-II Endoscopy

    The patients will receive a topical administration of probe (Bev-ICG) during the endoscopy. Then fluorescence imaging will be performed to guide the detection.

    Drug: Bev-ICG · Device: NIR-II fluorescence endoscopy platform

Interventions

  • DrugBev-ICG

    Probe targeting VEGF-A that is topically administrated during the endoscopy

  • DeviceNIR-II fluorescence endoscopy platform

    An endoscopic detection device which can detect and visualize NIR-II fluorescent signal during the endoscopy

06

What researchers measure

Primary outcomes

  1. Validation of NIR-II endoscope and probe targeting VEGF-A

    Demonstrate the feasibility of using the NIR-II endoscope and VEGF-A targeting fluorescent probe to image abnormal tissues of the gastrointestinal tract.

    Time frame: During endoscopy

07

Study locations

1 of 1 sites recruiting
  • Lidan Fu
    Beijing, Beijing 100190, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2023 (actual). Primary completion is estimated for May 2025, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2024
First posted
May 28, 2024
StartActual
Jul 20, 2023
Primary completionEst.
May 30, 2025
CompletionEst.
May 30, 2026
Last update
May 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06430372
Lead sponsor
Institute of Automation, Chinese Academy of Sciences
Responsible party
Zhenhua Hu (Professor, Institute of Automation, Chinese Academy of Sciences) — Principal investigator
First posted
May 28, 2024
Start date
Jul 20, 2023
Primary completion
May 30, 2025 (estimated)
Completion
May 30, 2026 (estimated)
Last update
May 13, 2025

Study contacts

Lidan Fu
Contact
fulidan2021@ia.ac.cn
17754927702

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion